Vulvodynia: chronic vulval pain — diagnosis, the Q-tip test, and treatment

Vulvodynia — chronic vulval pain lasting three or more months without an identifiable cause — affects an estimated 7–16% of women over their lifetime, making it at least as common as migraine or back pain in women. Yet half of those affected never seek care, and those who do wait on average five years for a diagnosis. The most common barriers are shame, dismissal (“it’s just in your head”), and clinicians who overlook the Q-tip test. Naming the condition accurately, offering a validated examination, and initiating evidence-based treatment substantially changes quality of life and sexual function.

A. Core clinical — the AU general-practice framework

ISSVD 2015 classification

The ISSVD/ISSWSH/IPPS 2015 consensus terminology (Bornstein J Sex Med 2016) classifies vulvodynia across four axes:

Axis	Categories
Site	Localised (vestibulodynia, clitorodynia, hemivulvodynia) or Generalised
Provocation	Provoked / Spontaneous / Mixed
Onset	Primary (present from first tampon/intercourse attempt) / Secondary
Temporal pattern	Intermittent / Persistent / Constant / Immediate / Delayed

Provoked vestibulodynia (PVD) — localised, provoked, vestibular — is the most common subtype and the one most responsive to pelvic floor physiotherapy and surgical intervention. Generalised vulvodynia tends to have a larger central sensitisation component and overlaps more frequently with other chronic pain conditions.

History

Key questions to ask:

• Where exactly is the pain, and does it extend beyond the vulva?
• Is it provoked by touch or penetration, spontaneous, or both?
• When did it start — at first tampon use, after an infection, after childbirth?
• What activities trigger or worsen it — sitting, cycling, tight clothing, intercourse?
• Assess impact on sexual function, relationships, mood, and avoidance behaviours
• Screen for comorbid conditions: interstitial cystitis/bladder pain syndrome (IC/BPS), irritable bowel syndrome (IBS), fibromyalgia, temporomandibular disorder — their co-occurrence is substantially above background, consistent with a shared central sensitisation mechanism

Medication review: current or past low-dose combined oral contraceptive use (particularly during adolescence) has been associated with provoked vestibulodynia in observational studies, though causality remains debated.

Examination

1. External inspection under adequate light — look for erythema, fissures, lichenification, leukoplakia, ulceration, or excoriation that would point to an alternative diagnosis (lichen sclerosus, lichen planus, herpes, Paget’s)
2. Q-tip (cotton-bud) test: Using a dry cotton bud, touch each point at 12, 3, 6, and 9 o’clock on the labia majora (control), then 4, 5, 7, and 8 o’clock on the vestibule (the modified mucosa between the hymenal ring and Hart’s line). In PVD, vestibular points elicit sharp, burning, or stinging pain disproportionate to light touch — patients often rate the vestibular contact as 7–10/10 when the labial control sites are 0–1/10
3. Vaginal swab (HVS + STI screen) before the test to exclude active infection — candidiasis must be excluded, as a first Candida episode sometimes precipitates persistent vestibular sensitisation
4. Internal pelvic floor assessment if tolerated — hypertonicity of levator ani is present in most women with PVD and is a primary treatment target

Investigations

There is no diagnostic test for vulvodynia — the diagnosis is clinical and by exclusion. Investigations are directed at ruling out causes:

• Vaginal swabs: microscopy, culture, STI screen (chlamydia, gonorrhoea, herpes PCR if ulceration)
• Biopsy: if skin change is present — do not biopsy normal-appearing vestibular tissue (may worsen sensitisation)
• Pap smear / cervical screening: up to date per National Cervical Screening Program schedule
• Pelvic ultrasound: if pelvic pain extends beyond the vulva or if adenomyosis, endometriosis, or ovarian pathology is suspected

B. Evidence base — what the trials show

Pelvic floor physiotherapy

Bergeron et al., Pain 2001 randomised 78 women with PVD to pelvic floor physiotherapy (surface EMG biofeedback), group CBT, or vestibulectomy. All three arms produced meaningful improvement, with physiotherapy and vestibulectomy equivalent at six months. This RCT established physiotherapy as a legitimate first-line option rather than a consolation. Goldfinger et al., J Sex Med 2009 confirmed sustained benefit two years after completing physiotherapy, with gains maintained in pain intensity, dyspareunia, and sexual function.

Cognitive-behavioural therapy

Bergeron et al., Lancet 2009 randomised 97 women with PVD to CBT, biofeedback, or topical lidocaine. CBT was equivalent or superior to medical management on pain outcomes and was superior on sexual function measures at 2.5-year follow-up. CBT targets pain catastrophising, hypervigilance, and avoidance behaviours that maintain and amplify central sensitisation.

Topical agents

5% lidocaine ointment (overnight): Zolnoun et al., Obstet Gynecol 2003 — open-label, but 57% of 61 women with PVD reported ≥50% reduction in introital pain after 7 weeks of nightly lidocaine application to the vestibule. Primarily used as a desensitisation strategy and sexual activity facilitator rather than a standalone treatment.

Topical gabapentin 6%: Boardman et al., Obstet Gynecol 2008 — retrospective series showing response in both PVD and generalised vulvodynia; used when oral neuromodulators are not tolerated.

Oral neuromodulators

Foster et al., Obstet Gynecol 2010 — the only adequately powered RCT of oral TCA (desipramine) vs lidocaine vs combination: no significant difference between arms, raising questions about the effect size of neuromodulators alone. Current practice uses them adjunctively in a multimodal regimen rather than as the primary therapy.

Vestibulectomy

Multiple case series and the Bergeron Pain 2001 RCT report 70–90% meaningful improvement in carefully selected women with localised PVD who have completed at least six months of conservative treatment without adequate response. Surgery removes the sensitised vestibular epithelium and advances vaginal mucosa. Patient selection is critical — outcomes are substantially worse when generalised or spontaneous components are present.

C. Multimodal management — the treatment ladder

Step 1: Trigger and irritant removal

Often the most impactful and quickest step:

• Remove all potential vestibular irritants: soaps, bubble bath, feminine hygiene products, antiseptic wipes, fabric softeners, synthetic underwear, thong underwear
• Use only warm water (no soap) to wash the vulva
• Switch to non-biological laundry detergent; wear white cotton underwear; remove underwear at night
• Avoid prolonged pad use; change frequently if using pads

Step 2: Pelvic floor physiotherapy

Refer early — ideally at the initial diagnostic visit — to a physiotherapist with specific training in pelvic health. Do not defer this while trying medication. Goals: reduce levator hypertonicity, down-train protective guarding, restore movement confidence, and address dyspareunia patterns. Find a practitioner via the Continence Foundation of Australia or Australian Pelvic Floor Physiotherapy.

Step 3: Topical lidocaine 5% ointment

Compounded or prescribed as an overnight application: a small amount of 5% lidocaine ointment applied to the vestibule at bedtime for six to eight weeks, wiped away in the morning. It is used as a desensitisation strategy and for intercourse facilitation (applied 15–20 minutes beforehand, with partner awareness of temporary penile anaesthesia). Lidocaine is not PBS-listed for this indication; it requires a private prescription and is typically compounded.

Step 4: Cognitive-behavioural therapy

Refer to a psychologist experienced in chronic pain or sexual pain — consider this a core treatment, not an adjunct. Pain catastrophising and avoidance behaviours are modifiable mediators of outcome. Pain Psychology is Medicare-rebatable under an MHC Plan (up to 10 sessions per calendar year under Better Access, MBS items 80000-series).

Step 5: Oral neuromodulators

Used when pelvic floor physio + topical measures + CBT have not provided sufficient relief, particularly in generalised or mixed subtypes:

Amitriptyline (TCA): start at 10 mg nocte, titrate by 10–25 mg every 2–4 weeks, usual target 50–75 mg nocte; monitor for anticholinergic effects, orthostatic hypotension, and sedation. Not PBS Authority-restricted for chronic pain in adults but requires standard prescription. SafeScript-monitored in Victoria.

Gabapentin or pregabalin: PBS Authority (Streamlined) listing for chronic neuropathic pain; both are SafeScript-monitored in all states. Counsel patients about dependence potential, CNS depression with alcohol and benzodiazepines, and the requirement to taper before stopping. Start low (gabapentin 100–300 mg nocte) and titrate slowly.

Step 6: Specialist interventions

For women who have not achieved adequate relief after ≥6 months of multimodal conservative therapy, refer to a specialist with expertise in vulval disease — typically a gynaecologist, dermatologist, or urogynaecologist:

• Botulinum toxin A injections to levator ani — evidence from small RCTs in refractory hypertonicity-predominant PVD
• Transcutaneous electrical nerve stimulation (TENS) or transcranial magnetic stimulation — investigational
• Vestibulectomy — for well-selected localised PVD refractory to conservative treatment; procedure removes sensitised vestibular epithelium and advances vaginal mucosa; 70–90% improvement in appropriate candidates

D. Australian operations

MBS items

Item	Description
3	Brief GP attendance (trigger/irritant counselling, initial assessment)
23	Standard GP consultation
36	Long consultation
44	Prolonged consultation
105/106	Specialist consultation (referred to gynaecologist/dermatologist)
715	Health Assessment (ATSI women — opportunistic screening for untreated vulval symptoms)
965/967	GP/specialist attendance longer (chronic pain review)
2715/2717	Telehealth GP/specialist (follow-up)
10960	Mental health care plan (for CBT referral under Better Access)
30071/30075	Vulvoscopy + biopsy (specialist, if skin change present)
71093	Gynaecological procedure — vestibulectomy
91790	Telehealth psychology
92029	In-room psychology under Better Access
92060	Mental health review

PBS prescribing

Gabapentin and pregabalin — PBS Authority (Streamlined) for chronic neuropathic pain, SafeScript-monitored in all states. Check current PBS Online criteria before prescribing.

Amitriptyline — general schedule; private prescription required for the neuropathic pain indication (listed PBS only for depression/nocturnal enuresis). Patients pay the private prescription cost unless they obtain a private script.

Topical lidocaine 5% — not PBS-listed for vulvodynia; private compounding prescription. Some compounding pharmacies offer standing accounts for practitioners who prescribe regularly.

Psychology under Better Access

Women with vulvodynia typically have significant anxiety, relationship distress, and psychological burden from years of diagnostic delay. The GP Mental Health Care Plan (MBS 2715/2717 + 10960) provides up to 10 rebated psychology sessions per calendar year. Pain-focused CBT and sex therapy (psychosexual counselling) are both appropriate referral targets.

Physiotherapy access

Pelvic floor physiotherapy is funded privately (not Medicare-rebatable as a standalone service unless attached to a Chronic Disease Management plan, items 10950–10970, where up to 5 allied health visits per year are available for patients with a chronic condition). The out-of-pocket cost is a common barrier — discuss early; waiting lists are long at public hospital pelvic health services.

E. Special populations

Adolescents and young women

Vulvodynia can present from the first tampon attempt or first intercourse — primary PVD has been reported as young as 13–15. This group is particularly vulnerable to diagnostic delay, blame, and the psychological impact of sexual dysfunction in early adulthood. Approach must be age-appropriate, trauma-informed, and include discussion of the biological (not psychological) basis of the condition. Referral to a paediatric and adolescent gynaecologist is appropriate for young women requiring examination under anaesthetic for biopsy or botulinum toxin.

Postpartum women

Perineal trauma, episiotomy, and prolonged second stage of labour are associated with de-novo PVD or worsening of pre-existing symptoms. Screen at 6-week postnatal check and at any later presentation with dyspareunia. Pelvic floor physiotherapy is highly appropriate and should be offered early alongside standard postnatal care.

Postmenopausal women

Genitourinary syndrome of menopause (GSM) — vaginal atrophy, dryness, dyspareunia — is common and distinct from, but can coexist with, vulvodynia. Treat GSM first with vaginal oestrogen or ospemifene; reassess residual vulval pain after GSM is treated. If a woman has long-standing PVD from premenopausal years that persists postmenopausally, the management ladder above applies; note that vestibulectomy outcomes are less well studied in postmenopausal women.

Women with comorbid central sensitisation conditions

The co-occurrence of IC/BPS, IBS, fibromyalgia, and vulvodynia in the same individual substantially above background prevalence supports shared central sensitisation mechanisms. In these women, a central neuromodulator strategy (amitriptyline, gabapentinoids, CBT, pain psychology, graded exercise) is particularly important alongside local vulval treatment. Coordinate care with gastroenterology (IBS), urology/urogynaecology (IC/BPS), and pain medicine as needed.

When to escalate

Refer to a specialist (gynaecologist, dermatologist, or urogynaecologist with vulval disease expertise) when:

• Diagnosis is in doubt — atypical appearance, skin change, ulceration, or failure to respond to first-line treatment
• Biopsy is required for a skin lesion (do not biopsy normal-appearing vestibule without specialist input)
• Vestibulectomy is being considered after ≥6 months of adequate conservative therapy
• Specialist botulinum toxin injection or other procedural interventions are needed
• Adolescent requiring examination under anaesthetic
• Significant sexual or relationship dysfunction that is not improving — consider referral to a psychosexual therapist
• Suspected IC/BPS or endometriosis contributing to pain

What this article is and is not

This article is an educational overview written for general-practice clinicians and informed patients. It describes evidence-based diagnostic and treatment approaches for vulvodynia but does not substitute for a full clinical assessment by a treating doctor. The optimal management of an individual patient may differ from what is described here based on their specific circumstances, comorbidities, medications, and preferences. All treatment decisions should be made in a therapeutic relationship with a qualified healthcare professional.

---

Sources cited

1. Bornstein J et al. — 2015 ISSVD/ISSWSH/IPPS Consensus Terminology, J Sex Med 2016
2. Pukall CF et al. — Vulvodynia: definition, prevalence, impact, and pathophysiological factors, Lancet 2016
3. Therapeutic Guidelines (eTG) — Gynaecology: vulval pain / vulvodynia
4. RANZCOG — Vulvodynia clinical resources
5. RACGP — Women’s health in general practice
6. Bergeron S et al. — Randomized comparison of pelvic floor biofeedback, CBT, and vestibulectomy, Pain 2001
7. Bergeron S et al. — Randomized clinical trial of CBT vs pain management, Lancet 2009
8. Goldfinger C et al. — Pelvic floor physical therapy outcomes at 2 years, J Sex Med 2009
9. Zolnoun DA et al. — Overnight 5% lidocaine ointment for vulvar vestibulitis, Obstet Gynecol 2003
10. Foster DC et al. — Oral desipramine and topical lidocaine RCT, Obstet Gynecol 2010
11. Boardman LA et al. — Topical gabapentin for vulvodynia, Obstet Gynecol 2008
12. Reed BD et al. — Oral contraceptives and vulvodynia, J Reprod Med 2006
13. AAFP — Vulvodynia: diagnosis and treatment, Am Fam Physician 2018
14. TGA — SafeScript real-time prescription monitoring
15. Jean Hailes — Vulvodynia
16. Pelvic Pain Foundation of Australia
17. HealthDirect — Vulvodynia
18. Australian Pain Society — chronic pelvic pain resources